The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition of UK-based Verona Pharma for ~$10 billion. This move aims to diversify ...

Merck headquarters in Rahway, NJ. RAHWAY, N.J.- Merck has completed its $10 billion buyout of the British biopharmaceutical company Verona. The deal was first announced in July. It brings the chronic ...

In one of the priciest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma, which has its U.S. headquarters in Raleigh, for roughly $10 billion.

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc. The Rahway pharma giant announced the deal for the biopharmaceutical company ...

Merck & Co. Inc. (NYSE:MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ...

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Verona Pharma plc is one of them. Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company developing ...

One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda. While it has been a beast for the business over the years, generating ...

Through this acquisition Merck will add Ohtuvayre ® (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today ...